Anti-Viral Drugs Market Future Demand, Top Players, Size, Share, Opportunities, Revenue and Growth Rate Through 2026

Anti-viral drugs are medicines which are used specially for treating viral infections. Most anti-viral drugs are used for particular viral infections, similar to antibiotics, while a broad-spectrum anti-viral drug is effective against a varied range of viruses. Antiviral drugs do not kill their target pathogen, instead they inhibit the development of those viruses.

The global anti-viral drugs market is projected to register a moderate growth rate in the pharmaceutical market and which is anticipated to increase due to rise in awareness level, increase in the diseased population and introduction of new drugs with improved efficacy.

Some major patents are reaching their expiry during forecast period, such as for Combivir, Sustiva, Tenofovir, Tamiflu, Relenza and Telbivudine. The patent expiries of these blockbuster drugs is expected to trigger generic competition in the antivirals therapeutics market, which will make the market more competitive.

The late stage pipeline drugs are expected to enter the market, which will positively impact the market. Most antivirals are considered comparatively harmless to host, and therefore are used to treat infections. They are different from viricides, which are not used for medication but can destroy or deactivate virus particles, either outside or inside the body.

The anti-viral drugs are used in the treatment of patients suffering from herpes viruses, HIV, influenza A and B viruses and the hepatitis B and C viruses.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/brochure/rep-gb-1951

Anti-viral Drugs Market: Drivers and Restraints

As of October 2013, according to WHO, there were around 35.3 Mn people globally, infected with HIV. Therefore, increased viral infection incidences is one of the important factors that drives the anti-viral drugs market growth. Because of the solid R&D activities, newer and advanced treatments and formulations, such as vaccines, combination therapy and others, are being introduced in the market.

Hence, strong R&D is one of the crucial factors in the anti-viral drugs market growth. On the other hand, high risk of failure, high cost of R&D and therapy, and government austerity are some of threats expected to hinder the growth of market.

These are some factors anticipated to fuel growth of global anti-viral drugs market within the forecast period of 2016-2026. However, increasing usage of natural products and high cost of developing drugs are the key challenges faced by the market.

Anti-viral Drugs Market: Overview

The generic market of anti-viral drugs is presently dominated by products such as didanosine, zidovudine, lamivudine and stavudine. The biggest driver of overall anti-viral drugs market is Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales which accounted for more than half the share of the market 2010.

At the end of 2012, 9.7 million people in low-income and middle-income countries were on antiretroviral treatment (ART). According to WHO, in 2012, number of patients on ART increased by 1.6 Mn, the largest increase in one year.

Nearly four out of five people were freshly put on treatment in the sub-Saharan Africa. In 21 African countries with a high burden of HIV, two out of three people in need are receiving treatment, and two out of three positive pregnant women are receiving antiretroviral drugs to prevent HIV transmission to their infants.

Inquire Before Buying Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-1951

Anti-viral Drugs Market: Regional Overview

Region wise, the global anti-viral drugs market is classified into regions namely, North America, Eastern Europe, Western Europe, Latin America, Japan, Asia-Pacific, Middle East and Africa. According to WHO, in countries with Major ART scale-up such as Brazil or China, the death rate among people living with HIV has decreased by 80%. In 2015, in India the number of people living with HIV were 2.1 Mn and in U.S. the number was around 1.2 Mn in the year 2013.

Anti-viral Drugs Market: Key Players

Some of the key players in global anti-viral drugs market, which are focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, include Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, AstraZeneca, Cipla, Schering-Plough, Johnson & Johnson, Merck & Co and others.

Read Related Reports:

https://medium.com/@shubham_62155/continuous-renal-replacement-therapy-market-trends-size-growth-insight-share-competitive-25bd7476daa4

https://shubhamc.livejournal.com/10887.html

https://flipboard.com/@shubhamchou2022/continuous-renal-replacement-therapy-market-size-future-trends-growth-key-fact-l339p831y

https://sedate-decade-bae.notion.site/Continuous-Renal-Replacement-Therapy-Market-Trends-Share-Size-Demand-Growth-Opportunities-Indus-2f67c083bc30486fa2e05e59460e0320

https://hackmd.io/@ShubhamChougale/BkEhOdUI9

https://fromfostercaretoceo.mn.co/posts/23259968?utm_source=manual

https://acatpg.mn.co/posts/23259971?utm_source=manualAbout Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Future Market Insights,

Unit No: 1602-006

Jumeirah Bay 2

Plot No: JLT-PH2-X2A

Jumeirah Lakes Towers

Dubai

United Arab Emirates

LinkedIn| Twitter| Blogs

Leave a comment

Your email address will not be published. Required fields are marked *